Bergen, Norway, 01 October 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that it will deliver an e-poster presentation at the Society for Immunotherapy of Cancer (SITC) 36[th] Annual Meeting, taking place online from 10-14 November 2021. Abstract titles have … Read more
Bergen, Norway, 30 September 2021 The Board of Directors in BerGenBio ASA (the “Company”) (OSE: BGBIO) have, to fulfil the Company’s obligations under the share option agreements and in accordance with the authorization granted by the general meeting on 19 March 2021, resolved to increase the Company’s share capital by NOK 13,750 by issuance of … Read more
Bergen, Norway, 7 September 2021 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, is pleased to announce the completion of patient recruitment into BGBC003 (ClinicalTrials.gov ID: NCT02488408), a Phase Ib/II multicenter open-label study of bemcentinib as a single agent and in combination with cytarabine or decitabine in patients … Read more
Bergen, Norway, 6 September 2021 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 31 August 2021 where the Company announced that the board of directors of the Company had resolved to increase the Company’s share capital in connection with the exercise of options pursuant to … Read more
Bergen, Norway, 31 August 2021 The Board of Directors in BerGenBio ASA (the “Company”) (OSE: BGBIO) have, to fulfil the Company’s obligations under the share option agreements and in accordance with the authorization granted by the general meeting on 19 March 2021, resolved to increase the Company’s share capital by NOK 1,500 by issuance of … Read more
Bergen, Norway, 26 August 2021 – Reference is made to the stock exchange notice published by BerGenBio ASA (the “Company”) (OSE: BGBIO) on 23 August 2021 where the Company announced that the board of directors of the Company had resolved to increase the Company’s share capital in connection with the exercise of options pursuant to … Read more
Bergen, Norway, 23 August 2021 The Board of Directors in BerGenBio ASA (the “Company”) (OSE: BGBIO) have, to fulfil the Company’s obligations under the share option agreements and in accordance with the authorization granted by the general meeting on 19 March 2021, resolved to increase the Company’s share capital by NOK 27,000 by issuance of … Read more
Bergen, Norway, 22 August 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical need, announces the appointment of Martin Olin as new Chief Executive Officer from 8 September 2021. Following twelve years as CEO of BerGenBio, Richard Godfrey has decided to step down as CEO of the … Read more
Bergen, Norway, 17 August 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces its results for the second quarter and first half of 2021. A presentation and live webcast by BerGenBio’s senior management will take place at 10.00 am CEST today, please see … Read more
Bergen, Norway, 6 August 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today announces changes to its clinical development team structure in preparation for late-stage clinical trials of lead candidate bemcentinib and increased activity in medical and scientific regulatory affairs. Prof. Hani Gabra has … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.